Fig. 10

A In vivo fluorescence imaging of orthotopic glioma-bearing mice treated with saline, DiR/PMs and DiR/Aβ-CN-PMs at 1 h, 2 h, 4 h, 24 h, and 36 h. B In vivo radiant efficiency of orthotopic glioma-bearing mice at 1 h, 2 h, 4 h, 24 h, and 36 h. Means ± SD, n = 3; *P < 0.05, **P < 0.01, ***P < 0.001 versus the DiR/Aβ-CN-PMs group. C Ex vivo imaging of brains from orthotopic glioma-bearing mice, which were administrated with saline, DiR/PMs and DiR/Aβ-CN-PMs at 1 h, 2 h, 4 h, 24 h, and 36 h. D Ex vivo fluorescence imaging of the major organs (hearts, livers, spleens, lungs and kidneys) from orthotopic glioma mice after the administration with saline, DiR/PMs and DiR/Aβ-CN-PMs at 1 h, 2 h, 4 h, 24 h, and 36 h. E Biodistribution of PTX/PMs and PTX/Aβ-CN-PMs in mice at 1 h, 2 h, 4 h, 8 h, 24 h, and 36 h after intravenous injection (n = 3 for each group at each time point). Means ± SD, n = 3; *P < 0.05, **P < 0.01, ***P < 0.001 versus the PTX/Aβ-CN-PMs group